EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

European Patent Office deals blow to pharma companies in dismissing their attempts to reinstate patents covering diabetes and obesity treatments | Inhibrx antibody patent upheld as Gilead subsidiary appeal is rejected.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

McGuireWoods expands team with ex-Novo Nordisk GC

21 November 2024 Firm appoints Craig Bleifer as a partner in its New York office | Bleifer brings more than three decades of experience, including senior roles at Novo Nordisk and Daiichi Sankyo.

Americas

Novo Nordisk targets Canada’s largest generics maker over diabetes drug

15 October 2024 Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

More on this story

Editor's picks

Editor's picks

More features